Reviewed by a Psychology Postgraduate (MA)
Psilocybin for depression is back in the headlines. In a small 2026 trial, 20 adults with treatment-resistant depression and chronic suicidal thoughts received a single 25-milligram dose of psilocybin alongside structured therapy support. Suicidal thinking dropped within a week, and by week 12, 70% of participants reported little or no suicidal ideation. But this is early evidence, not proof — the trial was tiny, and it had no control group.
If You Need Help Right Now
This article reports on a published clinical trial — it is not a treatment recommendation. If you are having thoughts of harming yourself, in the US you can call or text 988 any time to reach the Suicide and Crisis Lifeline, free and confidential, 24/7. You can also text HOME to 741741 to reach the Crisis Text Line.
What the Study Found
The trial was published online May 13, 2026, in The Journal of Clinical Psychiatry (van der Vaart et al., 2026; DOI: 10.4088/JCP.26m16338), and it returned to health-news headlines in early October 2026 when a wire feature on the findings began recirculating. So this is not a breaking-today story — it is a May study getting a second wave of attention, which is exactly when a careful second look is most useful.
Researchers at Sheppard Pratt in Baltimore — first author Andrew van der Vaart, MD, PhD, with chief science officer Scott T. Aaronson, MD — ran an open-label trial with 20 adults diagnosed with major depressive disorder and chronic suicidal ideation. Every participant had already failed at least two prior antidepressant treatments. Each received a single 25-mg dose of COMP360 psilocybin (a synthetic psilocybin made by Compass Pathways) inside a structured protocol: preparation sessions beforehand, supervised administration on dosing day, and integration sessions afterward. The team followed everyone for 12 weeks.
The headline results:
- Suicidal ideation fell significantly as early as one week after the single dose.
- By week 12, 70% of participants reported minimal or no suicidal ideation — roughly 14 of the 20.
- Depressive symptoms improved significantly at every post-treatment check.
- No serious adverse events were reported. Side effects were transient nausea, headache, and anxiety — though one participant with co-occurring PTSD had a panic attack on dosing day that required anti-anxiety medication.
For scale: about 1 in 20 US adults experiences serious suicidal thoughts each year, according to the National Alliance on Mental Illness — and NAMI’s helpline received 93,452 calls in 2025. Chronic suicidality, Aaronson said, “remains one of the most difficult symptoms to treat in psychiatry, particularly for patients who have not responded to conventional therapies.” That is the context in which a single-dose result like this lands.
One more honest detail, from Aaronson’s interview with PsyPost: some participants later admitted they had been more suicidal at screening than they claimed — because they were afraid of being excluded from the trial. People with immediate suicidal intent were excluded by design. So the sample was severe, but not the most acute.
Psilocybin for Depression: Does It Help? What This Study Actually Tested
Short answer: this study tested whether one supervised dose of psilocybin plus therapy could reduce chronic suicidal thoughts in people whose depression had resisted standard treatment. In this small group, it appeared to — but “appeared to” is doing heavy lifting, because there was no comparison group taking a placebo.
That caveat matters because the finding is genuinely unusual in one respect: people with chronic suicidal ideation have historically been excluded from psychedelic trials for safety reasons. This is one of the first studies to deliberately include them — which is why Sheppard Pratt framed it as a step toward research on a group with, in van der Vaart’s words, “a significant unmet need for new treatment options.”
Pause and Ask Yourself
When you read about a study like this, what do you notice first — the hope in the headline, or the size of the caveats? Neither reaction is wrong. Learning to hold both at once is the single most useful skill in reading mental-health news.
If tracking your own patterns would help, our Mood Check-In takes about two minutes.
Why Are Suicidal Thoughts So Hard to Treat?
To understand why researchers got excited, it helps to know why chronic suicidal thinking is one of psychiatry’s hardest problems. Standard antidepressants often take weeks to work — and for people with severe, persistent suicidal thoughts, they frequently don’t provide enough relief at all, as van der Vaart noted.
Picture someone — call her Maya, a composite of a pattern clinicians see constantly — who has tried two antidepressants, waited out the six-week lags, done everything “right,” and still wakes up each morning to the same flat, grey certainty that nothing will change. The thinking itself has become a groove. Psychologists call this cognitive rigidity: when the mind is depressed, it loses flexibility. The same few thoughts arrive on repeat, and alternatives feel unreachable — not unconvincing, but literally unthinkable. Hopelessness, the settled belief that the future holds nothing better, is one of the strongest known predictors of suicide risk.
Anything that genuinely loosens that rigidity, even briefly, is scientifically interesting. That is the doorway psychedelic research is walking through — not as a miracle cure, but as a possible crowbar for a stuck door.
What Might Psilocybin Be Doing to the Brain?
Psilocybin is a psychedelic compound found in certain mushrooms, studied in clinical trials only under strict medical supervision. This is where honesty requires the word might. Researchers hypothesize — they have not proven — that psychedelics temporarily loosen the brain’s default mode network, the system most active during self-referential thought. That is the “me, me, me” channel where rumination lives. The theory is that a loosened network lets rigid thought patterns flex, creating a window in which therapy can help install new ones.
Aaronson put the practical version plainly: “We are looking at treatments that can produce meaningful change within hours. Some participants leave the dosing session already feeling significantly different than when they arrived.” Hours, not the six weeks of a standard antidepressant — if the effect holds up in larger, controlled trials.
The study also turned up a quietly fascinating detail about expectation. Participants who arrived with stronger hopelessness and pessimism were less likely to respond early. “Expectancy is a strong force,” Aaronson said. Your mindset walking into a treatment appears to shape what the treatment can do — a finding with implications far beyond psychedelics, and a reminder that the placebo effect is not a trick but a real neurobiological force.
What the Study Can’t Tell Us
A fair reading of this trial means sitting with its limits, which the researchers stated themselves:
- There was no control group. Open-label means everyone knew they were getting psilocybin. The paper itself calls for future studies with “a suitable comparator group.” Without one, we cannot say the drug caused the improvement.
- Twenty people is tiny. Small samples can produce dramatic-looking percentages — 70% sounds enormous until you remember it means about 14 people.
- The most acute patients were excluded. Anyone with immediate suicidal intent or a medically significant attempt history was screened out, and some participants under-reported their severity to get in.
- It was industry-funded. Compass Pathways funded the study and supplied the drug — a disclosure the journal page carries openly, and a reason independent replication matters.
- Psilocybin is not an approved treatment. It remains a Schedule I substance federally, studied only under FDA investigational authorization. As van der Vaart warned: “Using psilocybin without clinical supervision and structured therapy can be dangerous because psychedelic drugs can have unpredictable effects.” This is not a do-it-yourself finding.
If You’re Struggling Right Now
None of this is a recommendation. It is a research report — interesting, early, and incomplete. If you are living with depression or suicidal thoughts, here is what exists today, proven and available:
- Reach a human now: in the US, call or text 988 (Suicide and Crisis Lifeline), free and confidential, 24/7. You can also text HOME to 741741 for the Crisis Text Line.
- Talk to a clinician about evidence-based options — several therapies and medications have strong track records for suicidal ideation, and supervised clinical settings offer newer approaches too. Tracking your mood over time (our Mood Check-In takes two minutes) gives you useful information to bring to that conversation.
Frequently Asked Questions
Does psilocybin cure depression?
No. A single small 2026 trial found that one supervised dose eased suicidal thoughts in 20 adults with treatment-resistant depression — but the study had no control group and cannot prove the drug caused the improvement. It is early evidence, not a cure.
Is psilocybin therapy legal in the US?
Not as a medical treatment. Psilocybin remains a Schedule I substance federally and is studied only under FDA investigational authorization in approved clinical trials. A few states and cities have decriminalized personal possession, which is not the same thing as legal medical treatment.
How fast did the study’s effects appear?
Reductions in suicidal ideation were statistically significant within one week of the single dose, and 70% of participants reported minimal or no suicidal ideation by week 12.
What were the risks in the trial?
Side effects included transient nausea, headache, and anxiety; one participant with co-occurring PTSD had a panic attack on dosing day that required medication. The researchers explicitly warn that unsupervised use can be dangerous because psychedelic effects are unpredictable.
Why were suicidal patients excluded from earlier psychedelic trials?
Safety concerns — researchers worried about adverse reactions in highly vulnerable people. This trial was notable precisely because it deliberately included people with chronic suicidal ideation, though not those with immediate intent.
Try It on Our Site
Free tools for understanding your own mind:
Mood Check-In Anxiety Check-In Challenge the Thought Relaxation Techniques
Related Reading
- Anhedonia: When Nothing Feels Good Anymore
- Why Fall Wrecks Your Mood: The Psychology of Seasonal Depression
- 1 in 6 US Teens Have Moderate to Severe Anxiety, New Study Finds
Key Takeaways
- A May 2026 Journal of Clinical Psychiatry trial (Sheppard Pratt; van der Vaart and Aaronson) gave 20 adults with treatment-resistant depression and chronic suicidal thoughts a single 25-mg dose of psilocybin with therapy support.
- Suicidal ideation dropped significantly within a week; by week 12, 70% reported little or no suicidal ideation, with no serious adverse events.
- The trial was open-label with no control group, tiny (n=20), excluded the most acute patients, and was funded by the drug’s maker — so it suggests, but cannot prove, a treatment effect.
- Researchers hypothesize psychedelics may loosen rigid thought patterns (including the default mode network’s self-referential loops), but this is theory, not established fact.
- Psilocybin is not an approved treatment and remains Schedule I; unsupervised use is dangerous. If you are struggling, call or text 988 in the US.
This article is for educational purposes only and is not a substitute for professional advice, diagnosis, or treatment. It reports on published research and is not a recommendation of any treatment. If you are struggling, consider speaking with a licensed mental health professional — and in the US, you can call or text 988 any time to reach the Suicide and Crisis Lifeline, free and confidential.